Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Taking Control: Treatment Strategies and Deep Brain Stimulation

At a Glance

Treatment for DYT17 primary dystonia is individualized: botulinum toxin is often used for symptoms in one area, oral medicines for symptoms in several areas, and deep brain stimulation may be considered when medicines are ineffective or poorly tolerated.

While the genetic label of DYT17 is rare, the strategy for managing its symptoms is well-established. Because your condition is a primary (isolated) dystonia, doctors have a personalized framework of tools to help restore your mobility and comfort. The goal is not just to stop the movements, but to do so with the fewest side effects possible.

A Personalized Treatment Framework

Treatment involves a shared-decision framework based on how much of your body is affected:

  1. Focal Symptoms (Affecting one area): The first line of defense is often Botulinum Toxin injections [1][2].
  2. Segmental or Generalized Symptoms (Affecting multiple areas): Doctors typically introduce Oral Medications to provide body-wide relief [2].
  3. Refractory Symptoms (Not responding to medicine): If medications fail to provide adequate improvement or cause too many side effects, Deep Brain Stimulation (DBS) becomes a primary consideration [3][4].

Oral Medications: The “Body-Wide” Approach

Oral medications work by changing the chemical signals in your brain’s movement centers. You should never start, stop, or change doses abruptly without your prescriber’s guidance.

  • Anticholinergics (e.g., Trihexyphenidyl): These are often effective for generalized dystonia [2]. However, they can cause memory problems, blurred vision, fast heartbeat, dry mouth, urinary retention, and problems in people with narrow-angle glaucoma [5][6].
  • Muscle Relaxants (e.g., Baclofen): These help reduce muscle stiffness but can lead to sedation, falls, or a feeling of weakness [7]. Abrupt withdrawal can be dangerous.
  • Benzodiazepines (e.g., Clonazepam): These are sometimes used for their muscle-relaxing effects, though they can cause sleepiness, dependence, withdrawal risks, and respiratory depression [8].

Botulinum Toxin: Targeted Relief

Botulinum Toxin (like Botox or Dysport) is a protein injected directly into the overactive muscles to temporarily block the signal telling them to contract [9].

  • Brand Differences: It is important to know that different brands are not interchangeable; 100 units of Botox do not equal 100 units of Dysport [10][11].
  • Generalized Dystonia: While injections are excellent for “hot spots” (like a twisting neck), there is a limit to how much toxin can be used safely in one session. The benefit is temporary (typically lasting a few months) and requires an experienced clinician. When used in the neck or throat, injections can occasionally cause swallowing or breathing difficulties [2].

Deep Brain Stimulation (DBS)

For many with generalized dystonia, DBS is an established surgical option. It involves surgically placing thin wires into a part of the brain called the Globus Pallidus internus (GPi) [1][4]. These wires are connected to a small device in your chest that sends electrical pulses to adjust your brain’s movement circuits.

  • Efficacy: Studies show an average motor improvement of 58% to 65% in broader primary dystonia cohorts, though DYT17-specific data is extremely limited [12][13]. DBS is a treatment, not a cure, and symptoms like pain, speech, or fixed joint contractures may not improve as much as abnormal movements.
  • Long-Term Benefit: Research shows that benefits often persist for years, though you must commit to repeated programming visits, surgical risks (such as bleeding or infection), and battery replacements [14][13].
  • The Window of Opportunity: You do not have to wait until you are completely immobile to consider DBS. In fact, a shorter disease duration and the absence of permanent joint stiffness (contractures) are predictors of a better outcome [15][16].

Working closely with your multidisciplinary team helps you weigh these risks and choose the right interventions at the right time.

Common questions in this guide

What treatments are used for DYT17 primary dystonia?
Treatment depends on how many body areas are affected and how well symptoms respond. Botulinum toxin is often used for symptoms in one area, oral medicines may help when several areas are involved, and deep brain stimulation may be considered when symptoms remain disabling or medicines cause unacceptable side effects.
When might deep brain stimulation be considered for DYT17 dystonia?
DBS may be considered when medications do not provide enough improvement or cause too many side effects, particularly in generalized primary dystonia. The usual target discussed for dystonia is the globus pallidus internus, or GPi, but DYT17-specific evidence is limited and candidacy must be assessed individually.
What medicines can be used for primary dystonia, and what side effects should I know about?
Common oral options include trihexyphenidyl, baclofen, and clonazepam. Depending on the medicine, side effects can include dry mouth, blurred vision, memory or concentration problems, sleepiness, weakness, falls, dependence, or breathing problems. Do not start, stop, or change these medicines without guidance from the prescriber.
How do botulinum toxin injections help dystonia?
Botulinum toxin is injected into overactive muscles to temporarily reduce the signals that make them contract. Benefits usually last a few months, and brands such as Botox and Dysport are not interchangeable by unit. Injections near the neck or throat can occasionally cause swallowing or breathing difficulties.
What does DBS involve, and does it cure dystonia?
DBS involves placing thin wires in the brain and connecting them to a device in the chest that sends electrical pulses to movement circuits. It can improve abnormal movements but is a treatment rather than a cure, and it requires programming visits, surgical-risk planning, and eventual battery replacement.
Is it better to consider DBS before dystonia causes fixed joint contractures?
A shorter duration of dystonia and the absence of permanent joint stiffness or contractures are associated with better DBS outcomes. You do not necessarily need to wait until you are unable to move, but the right timing depends on your symptoms, prior treatments, overall health, and specialist evaluation.

Get notified when new evidence is published on Primary dystonia, DYT17 type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Generalized dystonia unraveled: Molecular mechanisms, diagnostic strategies, and treatment paradigms.

    Yarahmadi F, Shoiebi A, Shariati M, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(11)):5657-5669 doi:10.1007/s10072-025-08404-3.

    PMID: 40841848
  2. 2

    Update on current and emerging therapies for dystonia.

    Lizarraga KJ, Al-Shorafat D, Fox S

    Neurodegenerative disease management 2019; (9(3)):135-147 doi:10.2217/nmt-2018-0047.

    PMID: 31117876
  3. 3

    Brain Stimulation for Torsion Dystonia.

    Fox MD, Alterman RL

    JAMA neurology 2015; (72(6)):713-9 doi:10.1001/jamaneurol.2015.51.

    PMID: 25894231
  4. 4

    Botulinum Toxin and Deep Brain Stimulation in Dystonia.

    de Souza JCC, Falcone ACM, Barbosa RMG, et al.

    Toxins 2024; (16(6)) doi:10.3390/toxins16060282.

    PMID: 38922176
  5. 5

    Botulinum toxin type A versus anticholinergics for cervical dystonia.

    Rodrigues FB, Duarte GS, Castelão M, et al.

    The Cochrane database of systematic reviews 2021; (4()):CD004312 doi:10.1002/14651858.CD004312.pub3.

    PMID: 33852744
  6. 6

    Physician Approaches to the Pharmacologic Treatment of Dystonia in Cerebral Palsy.

    Lott E, Fehlings D, Gelineau-Morel R, et al.

    medRxiv : the preprint server for health sciences 2024; doi:10.1101/2024.02.01.24302121.

    PMID: 38352331
  7. 7

    Medication use in childhood dystonia.

    Lumsden DE, Kaminska M, Tomlin S, Lin JP

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2016; (20(4)):625-9.

    PMID: 26924167
  8. 8

    Patient-reported responses to medical treatment in primary dystonia.

    Woo KA, Kim HJ, Yoo D, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2020; (75()):242-244 doi:10.1016/j.jocn.2020.03.025.

    PMID: 32249176
  9. 9

    Update on the Use of Botulinum Toxin Therapy for Focal and Task-Specific Dystonias.

    Lungu C, Ahmad OF

    Seminars in neurology 2016; (36(1)):41-6 doi:10.1055/s-0035-1571211.

    PMID: 26866495
  10. 10

    Botulinum toxin type-A preparations are not the same medications - clinical studies (Part 2).

    Sławek J, Bogucki A, Bonikowski M, et al.

    Neurologia i neurochirurgia polska 2021; (55(2)):141-157 doi:10.5603/PJNNS.a2021.0028.

    PMID: 33797748
  11. 11

    A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.

    Rystedt A, Zetterberg L, Burman J, et al.

    Clinical neuropharmacology 2015; (38(5)):170-6 doi:10.1097/WNF.0000000000000101.

    PMID: 26366966
  12. 12

    Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study.

    Reich MM, Horn A, Lange F, et al.

    Brain : a journal of neurology 2019; (142(5)):1386-1398 doi:10.1093/brain/awz046.

    PMID: 30851091
  13. 13

    Long-term effects of bilateral pallidal deep brain stimulation in dystonia: a follow-up between 8 and 16 years.

    Krause P, Völzmann S, Ewert S, et al.

    Journal of neurology 2020; (267(6)):1622-1631 doi:10.1007/s00415-020-09745-z.

    PMID: 32055996
  14. 14

    Long-Term Outcomes on Pallidal Neurostimulation for Dystonia: A Controlled, Prospective 10-Year Follow-Up.

    Krause P, Mahlknecht P, Skogseid IM, et al.

    Movement disorders : official journal of the Movement Disorder Society 2025; (40(6)):1098-1111 doi:10.1002/mds.30130.

    PMID: 39907392
  15. 15

    Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome.

    Tisch S, Kumar KR

    Frontiers in neurology 2020; (11()):630391 doi:10.3389/fneur.2020.630391.

    PMID: 33488508
  16. 16

    Arching deep brain stimulation in dystonia types.

    Kim HJ, Jeon B

    Journal of neural transmission (Vienna, Austria : 1996) 2021; (128(4)):539-547 doi:10.1007/s00702-021-02304-4.

    PMID: 33740122

This page is for informational purposes only and does not constitute medical advice. Your neurologist and multidisciplinary team can help tailor medications, botulinum toxin, or DBS to your situation.